EGFR and neoplasm: A retrospective analysis of the US-American CALGB-80405 trial demonstrated a statistically significant difference in OS between patients treated with anti-EGFR based and anti-VEGF based therapy in left-sided mCRC (36.0 versus 31.4 months; HR: 0.82; p = 0.01) but not in right-sided tumours (16.7 versus 24.2 months; HR: 1.26; p = 0.08, 9].